Zykadia (Ceritinib) Patent Expiration, LOE Window & CMS Spending
Zykadia (Ceritinib) by Novartis: FDA Orange Book core substance LOE 2032-01-18 (last listed 2037-12-13), 0 AB generics, $5.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N211225 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-01-18 |
| Last Listed Patent or Exclusivity Date | 2037-12-13 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.0M |
| 2024 Medicare Part D Spend | $4.6M |
| 2024 Medicaid Spend | $492K |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 24.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.